Zim Laboratories Limited operates within India and beyond, involved in the production of formulated drugs and pre-formulation ingredients. They market and distribute these products internationally as well. The company’s global reach includes wholly-owned subsidiaries that engage in pharmaceutical manufacturing, wholesale distribution, market research, and research & development activities.

Zim Laboratories Limited focuses on designing, producing, and delivering unique generic pharmaceutical formulations and pre-formulation intermediaries in specific therapeutic areas. They also offer diverse delivery solutions that set apart their generic pharmaceutical products. This involves the entire process from conceptualization and development to registration filing, manufacturing, and supply of pharmaceutical goods.

Technical commentary: Last month, on July 28th, the company’s stock prices experienced a notable 9% surge. This surge marked a significant breakout from a 150-day-long rounding bottom pattern. The foundation of this rounding bottom was formed by an inverted head and shoulders pattern, adding to the confidence that the company could be poised for unexpected success. Following the breakout from this foundation, there was a retest of the upper boundary of the rounding bottom pattern. This retest occurred alongside the formation of an ascending broadening wedge pattern, which further strengthens the positive outlook.

“The rationale for waiting until a pullback to establish a position lies in the benefits of pullback trading strategy. The best feature of pull back trading is that you trade at a time when no one have interest in it. this will help you to fill your bids at a cheap price even in illiquid scrips.”